POR FESR 2014-2020 Regione Umbria
Progetto finanziato dalla Regione Umbria nel quadro del “Bando a sostegno dei progetti complessi di ricerca & sviluppo - POR FESR 2014-2020”. Il programma strategico “Piattaforma integrata per la ricerca e lo…
α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Inhibitors as Novel Modulators of NAD+ Biosynthesis
TES Pharma announces the publication of a Journal of Medicinal Chemistry paper “α-Amino-β-carboxymuconate-ε-semialdehyde Decarboxylase (ACMSD) Inhibitors as Novel Modulators of De Novo Nicotinamide Adenine Dinucleotide (NAD+) Biosynthesis” (DOI: 10.1021/acs.jmedchem.7b01254) covering the…
Umbria ERDF Project
TES announces the successful awarding of a European Regional Development Fund, Umbria project, "Integrated platform for innovative drug research and development for oncological and metabolic diseases ", partnered with leading…
TES Pharma and École Polytechnique Fédérale de Lausanne (EPFL) Announce R&D Collaboration on Small Molecule Therapies for Metabolic Disorders and Age-Related Diseases
TES Pharma and EPFL announce a new research and development collaboration on novel small molecule modulators of the kynurenine pathway as therapies for metabolic disorders and age-related diseases. The collaboration…
First α-Amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) Patent Published
TES Pharma announces the granting of the first ACMSD patent, US9,708,272(B2), in its ACMSD patent portfolio. The patent discloses the first know drug-like inhibitors of ACMSD. Compounds from our ACMSD…